Jiangsu vcare pharmaceutical technology co., LTD
35
8
8
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 35 trials
100.0%
+13.4% vs industry average
14%
5 trials in Phase 3/4
0%
0 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
Role: lead
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
Role: lead
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Role: lead
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
Role: lead
Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function
Role: lead
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Role: lead
A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases
Role: lead
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Role: lead
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Role: lead
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Role: lead
Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
Role: lead
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Role: lead
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
Role: lead
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
Role: lead
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Role: lead
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Role: lead
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Role: lead
Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
Role: lead
The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers
Role: lead
Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis
Role: lead